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Abstract
Nitric oxide (NO) generating (NOGen) materials have been shown previously to create localized
increases in NO concentration by the catalytic decomposition of blood S-nitrosothiols (RSNO) via
copper (Cu)-containing polymer coatings and may improve extracorporeal circulation (ECC)
hemocompatibility. In this work, a NOGen polymeric coating composed of a Cuo-nanoparticle (80
nm)-containing hydrophilic polyurethane (SP-60D-60) combined with the intravenous infusion of
an RSNO, S-nitroso-N-acetylpenicillamine (SNAP), is evaluated in a 4 h rabbit thrombogenicity
model and the anti-thrombotic mechanism is investigated. Polymer films containing 10 wt.% Cuo-
nanoparticles coated on the inner walls of ECC circuits are employed concomitantly with systemic
SNAP administration (0.1182 μmol/kg/min) to yield significantly reduced ECC thrombus
formation compared to polymer control + systemic SNAP or 10 wt.% Cu NOGen + systemic
saline after 4 h blood exposure (0.4 ± 0.2 NOGen/SNAP vs 4.9 ± 0.5 control/SNAP or 3.2 ± 0.2
pixels/cm2 NOGen/saline). Platelet count (3.9 ± 0.7 NOGen/SNAP vs 1.8 ± 0.1 control/SNAP or
3.0 ± 0.2 × 108/ml NOGen/saline) and plasma fibrinogen levels were preserved after 4 h blood
exposure with the NOGen/SNAP combination vs either the control/SNAP or the NOGen/saline
groups. Platelet function as measured by aggregometry (51 ± 9 NOGen/SNAP vs 49 ± 3%
NOGen/saline) significantly decreased in both the NOGen/SNAP and NOGen/saline groups while
platelet P-selectin mean fluorescence intensity (MFI) as measured by flow cytometry was not
decreased after 4 h on ECC to ex vivo collagen stimulation (26 ± 2 NOGen/SNAP vs 29 ± 1 MFI
baseline). Western blotting showed that fibrinogen activation as assessed by Aγ dimer expression
was reduced after 4 h on ECC with NOGen/SNAP (68 ± 7 vs 83 ± 3% control/SNAP). These
results suggest that the NOGen polymer coating combined with SNAP infusion preserves platelets
in blood exposure to ECCs by attenuating activated fibrinogen and preventing platelet
aggregation. These NO-mediated platelet changes were shown to improve thromboresistance of
the NOGen polymer-coated ECCs when adequate levels of RSNOs are present.
© 2011 Elsevier Ltd. All rights reserved.
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1. Introduction
The biocompatibility of polymeric tubing used in extracorporeal circulation is highly
dependent on the suppression of both the contact coagulation pathway (i.e., fibrin formation)
and the activation of circulating blood platelets. Recently, it has been recognized that
preventing fibrin formation as well as platelet and monocyte activation while patients are on
chronic extracorporeal life support (ECLS), is desirable for increasing the success rate of
clinical outcomes. Nitric oxide, an endogenous platelet inhibitor and vasodilator, has already
been incorporated into polymeric tubings to mimic its endogenous effects on platelet
activation. Indeed, a number of NO releasing (NORel) polymer coatings have been studied
over the last decade using polymer-embedded NO donor molecules, such as
diazeniumdiolated dibutylhexanediamine (DBHD/N2O2) [1–5]. The possible role of NO
released locally from polymeric coatings has been found to mediate the level of platelet
membrane glycoprotein, P-selectin, and the influence the monocyte integrin, CD11b, in
thrombogenicity [1]. However, due to the limited reservoir of the NO donors in the polymer
coatings, the NO release approach is only suitable for biomedical devices that require short-
term blood ECC contact times, such as hemodialysis and coronary artery bypass surgery, but
not for long-term (i.e., weeks or months) of operation. To maintain NO production for
extended periods of time it may be possible to take advantage of endogenous species such as
nitrosothiols (RSNO) that are constantly produced endogenously (from NO generated by
nitric oxide synthase) to produce NO in situ at a polymer/blood interface.
Nitric oxide generating (NOGen) polymers contain an immobilized catalyst such as copper
(Cu) nanoparticles or a Cu(II) ion/ligand complex that can liberate NO from circulating S-
nitrosothiols (RSNO) at the blood/polymer interface [6–9]. RSNOs, which serve as
intermediates in the metabolism and transport of biologically active NO, can exist in two
forms, the diffusion-limited high molecular weight (HMW) RSNOs such as S-nitroso-
albumin and the more mobile low molecular weight (LMW) RSNOs such as S-
nitrosocysteine and S-nitrosoglutathione [10]. Scharfstein et al. reported that the transfer of
NO or transnitrosylation between the HMW and the LMW RSNOs occurs rapidly and
completely under physiological conditions [10]. The effectiveness of the NOgen polymers to
release NO is dependent upon the level of reduced catalyst (Cu(I)) and the availability of
LMW RSNOs to the catalytic Cu(I) species after its reduction from Cu(II). The redox
cycling of Cu(II) and Cu(I) and then back to Cu(II) if other reducing agents like thiols and
ascorbate are present Eq. (1) can provide a continuous NO generation from LMW RSNOs as
long as the total circulating RSNO level is maintained at adequate levels through exogenous
RSNO delivery and transnitrosylation processes [11–15].
(1)
However, the effects of the NO produced from circulating RSNOs, after contact with the
NOGen polymer coatings, on preserving platelet count and function remains unclear.
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To test the hypothesis that sustainable NO generation (NOGen) due to the catalytic
decomposition of RSNOs mediates circulating platelet and monocyte quiescence, the present
study was designed to evaluate if platelet P-selectin and monocyte CD11b expressions are
preserved by the NO released from the copper nanoparticle doped polymer-coated ECC
circuits and exogenous SNAP. The copper nanoparticles within the polymer coatings can
slowly corrode to produce sparingly soluble oxides and other copper salts that provide low
levels of catalytically active Cu(I)/Cu(II) ions at polymer/solution interfaces. The copper
ions can then interact with RSNOs in the flowing blood to locally produce elevated levels of
NO. Therefore, we investigated, in a rabbit model, if the preservation of platelets was
mediated by direct platelet attenuation as measured by platelet membrane P-selectin
expression and/or a conformational change in plasma fibrinogen as measured by the Aγ
dimer formation after 4 h of blood exposure to NOGen ECC circuits formulated with copper
nanoparticles.
2. Materials and methods
2.1. Materials
Tygon® poly(vinyl chloride) (PVC) tubing was purchased from Fisher Healthcare (Houston,
TX). The tecophilic polyurethane, SP-60D-60, was a product of Lubrizol Advanced
Materials, Inc. (Cleveland, OH). Tetrahydrofuran (THF) was obtained from Sigma–Aldrich
Chemical Co. (St.Louis, MO). Copper nanoparticles (80 nm) were obtained from Sigma–
Aldrich (St. Louis, MO). The mouse antibodies for human CD61 (GPIIIa) FITC and human
P-selectin glycoprotein (CD62P) PE were from AbD Serotec (Raleigh, NC) as well as
Mouse isotype controls for IgG1 FITC and IgG1 PE. For monocyte surface receptor
determination of the integrin, CD11b, and the surface antigen CD14, the rat antibody for
mouse CD11b Alexa Flour 488 and mouse antibody for human CD 14 PE, respectively,
from AbD Serotec were used. The antibody clones for P-selectin, CD11b and CD14 have
been previously shown to have cross-reactivity to the rabbit [16–19]. The rat isotype control
for IgG2b Alexa Fluor 488 and the mouse isotype control for IgG2a PE were purchased from
AbD Serotec. Human plasma fibrinogen containing ≥90% clottable proteins was obtained
from Calbiochem (La Jolla, CA) and fluorescein-labeled goat IgG (polyclonal) against
denatured human fibrinogen was purchased from MP Biomedicals, LLC (Solon, OH). The
96-well microtiter plates (black, polypropylene) used for fluorescence measurements were
obtained from Nalge Nunc International (Rochester, NY). All other reagents were of the
highest purity available.
2.2. Preparation of NOGen polymeric coatings and ECC construction
A polymer coating solution containing 1, 5 and 10 wt.% copper nanoparticles in SP-60D-60
polyurethane was prepared using a method previously reported [7]. Briefly, double layers of
polymeric coatings which included an active layer and a top layer were individually coated
on the inner wall of the Tygon® tubing that formed the ECC. The active layer was prepared
by dissolving 700 mg SP-60D-60 in 12 ml THF along with 1–10 wt.% copper nanoparticles
(Soln A). Copper nanoparticles were sonicated in THF before mixing with the SP-60D-60/
THF solution to obtain a more uniform dispersion. The top layer was formulated using 700
mg SP-60D-60 in 12 ml THF (Soln B).
The ECC configuration used in this study was previously described [1]. The ECC consisted
of a 16-gauge and 14-gauge IV polyurethane angiocatheters (Kendall Monoject Tyco
Healthcare Mansfield, MA), two 16 cm lengths of ¼ inch inner diameter (ID) Tygon®
tubing and a 8 cm length of 3/8 inch ID Tygon® tubing which created a thrombogenicity
chamber where thrombus could form more easily due to more turbulent blood flow. The
ECC was pieced together, starting at the left carotid artery side, with the 16-gauge
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angiocatheter, one 15 cm length ¼ inch ID tubing, the 8 cm length thrombogenicity
chamber, the second 15 cm length ¼ inch ID tubing and finally the 14-gauge angiocatheter.
The angiocatheters were interfaced with tubing using 2 luer-lock PVC connectors. The 3/8
inch ID tubing and the ¼ inch tubing were welded together using THF.
The assembled ECC was coated first with two active coats of Soln A, followed by one top
coat of Soln B. The circuitry was filled with each solution then removed. Each coat was
allowed to dry for at least 1 h. The finished ECCs were allowed to cure under nitrogen
conditions for 20 min, and then dried under vacuum for 2 d. (Fig. 1B).
2.3. NO release measurements
NO released from the NOGen polymer-coated circuits was measured via a Sievers
chemiluminescence NO Analyzer® (NOA), model 280 (Boulder, CO). as described
previously [7]. Briefly, S-nitrosoglutathione (GSNO), used as the substrate for the copper-
containing polymer, was prepared by the reaction of equimolar glutathione (GSH) and
NaNO2 in 0.06 M H2SO4. The prepared GSNO (1 μM), 30 μM GSH and 5 μM EDTA, which
was used to chelate any contaminant metal ions, were added to an amber reaction vessel
containing phosphate-buffered saline (PBS) at 37 °C. After a 5 min measurement of baseline
NO level, a centimeter square sample of the copper-containing circuitry was then placed in
the reaction vessel containing the substrate solution at 37 °C. NO was continuously swept
from the headspace of the sample vessel and purged from the bathing solution with a
nitrogen sweep gas and bubbler into the chemiluminescence detection chamber. The flow
rate was set to 200 ml/min with a chamber pressure of 5.4 Torr and an oxygen pressure of
6.0 psi. Using this method, a uniform segment of NOGen polymer was tested for NO release
prior to and 4 h after blood exposure.
2.4. In vitro fibrinogen adsorption assay
The in vitro fibrinogen adsorption immunofluorescence assay was performed in a 96-well
format. The NOGen and control polymer solutions used in preparing the ECC was also used
to coat microwells of the 96-well microtiter plates. In addition, similar polymer drying
conditions were used for the ECC and 96-well preparations. Briefly, human fibrinogen was
diluted to 3 mg/ml with Dulbecco’s phosphate-buffered saline (dPBS) without CaCl2 and
MgCl2 (Gibco Invitrogen Grand Island, NY), equivalent to the human plasma concentration,
and then used for the adsorption experiments [20]. One hundred μl of this solution were
added to each well for 1.5 h at 37 °C, followed by eight washing steps using 100 μl of wash
buffer, which consisted of a 10-fold dilution of AbD Serotec Block ACE buffer (Raleigh,
NC) and 0.05% Tween 20 (Calbiochem La Jolla, CA). To block nonspecific antibody
binding, wells were incubated with 100 μl blocking buffer (4-fold dilution of Serotec Block
ACE buffer) for 30 min at 37 °C. After rinsing 3 times with wash buffer (100 μl per well) a
background fluorescence measurement of the plates was performed at 485 nm (excitation)
and 528 nm (emission) on a Synergy 2 fluorescence microplate reader (Biotek Winooski,
VT). To detect the adsorbed fibrinogen, goat anti-human fibrinogen antibody was diluted
(1:10) in a 10-fold dilution of the Serotec Block ACE buffer and 100 μl of this final solution
was added to each well. The antibody was allowed to bind to the surface-adsorbed
fibrinogen for 1.5 h at 37 °C. Human fibrinogen adsorption to non-coated polypropylene
was used as an internal control to normalize the fluorescence signals within different plates.
A standard curve for fibrinogen was obtained on each plate from 0 to 3000 μg/ml. All
measurements were done in triplicate and performed with the Synergy 2 fluorescence reader.
2.5. The rabbit thrombogenicity model
The animal handling and surgical procedures were approved by the University Committee
on the Use and Care of Animals in accordance with university and federal regulations. A
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total of 32 Zealand white rabbits (Myrtle’s Rabbitry, Thompson’s Station, TN) were used in
this study. All rabbits (2.5–3.5 kg) were initially anesthetized with intramuscular injections
of 5 mg/kg xylazine injectable (AnaSed® Lloyd Laboratories Shenandoah, Iowa) and 30
mg/kg ketamine hydrochloride (Hospira, Inc. Lake Forest, IL). Maintenance anesthesia was
administered via a diluted intravenous (IV) infusion of ketamine (2 mg/ml) at a rate of 2.62
mg/kg/h. In order to maintain blood pressure stability, IV fluids of Lactated Ringer’s were
given at a rate of 33 ml/kg/h. The paralytic, pancuronium bromide (0.33 mg/kg, IV), was
administered to have animal totally dependent upon mechanical ventilation which was done
via a tracheotomy and using a Sechrist Infant Ventilator Model IV-100 (Anaheim, CA). For
monitoring blood pressure and collecting blood samples, the rabbits’ right carotid artery was
cannulated using a 16-gauge IV angiocatheter (Jelco®, Johnson & Johnson, Cincinnati,
OH). Blood pressure and derived heart rate were monitored with a Series 7000 Monitor
(Marquette Electronics Milwaukee, WI). Body temperature was monitored with a rectal
probe and maintained at 37 °C using a water-jacketed heating blanket. Prior to placement of
the arteriovenous (AV) custom-built extra-corporeal circuit (ECC), the rabbit left carotid
artery and right external jugular vein were isolated and baseline hemodynamics as well as
arterial blood pH, pCO2, pO2, total hemoglobin and methemoglobin were measured using an
ABL 725 blood-gas analyzer and an OSM3 Hemoximeter (Radiometer Copenhagen
Copenhagen, DK). In addition, baseline blood samples were collected for platelet and total
white blood cell (WBC) counts which were measured on a Coulter Counter Z1 (Coulter
Electronics Hialeah, FL). Plasma fibrinogen levels were determined using a Dade Behring
BCS Coagulation Analyzer (Siemans Deerfield, IL), activated clotting times (ACT) were
monitored using a Hemochron Blood Coagulation System Model 801 (International
Technidyne Corp. Edison, NJ), platelet function was assessed using a Chrono-Log optical
aggregometer model 490 (Havertown, PA) and platelet P-selectin and monocyte CD11b
expression were determined utilizing fluorescent-activated cell sorting (FACS) with a
Becton Dickinson FACSCalibur flow cytometer (San Jose, CA).
After baseline blood measurements, the AV custom-built ECC was placed into position by
cannulating the left carotid artery for ECC inflow and the right external jugular vein for
ECC outflow. The flow through the ECC was started by unclamping the arterial and venous
sides of ECC and blood flow in circuit was monitored with an ultrasonic flow probe and
flow meter (Transonic HT207 Ithaca, NY). Animals were not systemically anticoagulated
during the experiments. For 1, 5 and 10 wt.% of the copper nanoparticle-coated ECC
studies, 0.1182 μmol/kg/min infusion of the RSNO, SNAP, was started after the ECC blood
flow was initiated. A separate group of animals, consisting of 10 wt.% copper-coated ECC
plus a 0.0591 μmol/kg/min infusion (i.e., ½ RSNO dose) of SNAP, was evaluated.
After 4 h on ECC plus either saline or SNAP infusion, the circuits were clamped, removed
from animal, rinsed with 60 ml of saline and drained. Any residual thrombus in the larger
tubing of ECC (i.e., thrombogenicity chamber) was photographed and the degree of
thrombus image was quantitated using Image J imaging software from National Institutes of
Health (Bethesda, MD). Prior to euthanasia, all animals received a dose of 400 U/kg sodium
heparin to prevent necrotic thrombosis. The animals were euthanized using a dose of Fatal
Plus (130 mg/kg sodium pentobarbital) (Vortech Pharmaceuticals Dearborn, MI). All
animals underwent gross necropsy after being euthanized, including examination of the
lungs, heart, liver and spleen for any signs of thromboembolic events.
2.6. Blood sampling
Rabbit whole blood samples were collected in non-anticoagulated 1 cc syringes for ACT,
10% anticoagulant containing sodium citrate, sodium phosphate and dextrose (ACD)
(Hospira,Inc. Lake Forest, IL) in 3 cc syringes for cell counts, aggregometry and FACS
analysis, and 1 cc syringes containing 40 U/ml of sodium heparin (APP Pharmaceuticals,
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LLC Schaumburg, IL) for blood-gas analysis. Following the initiation of ECC blood flow,
blood samples were collected every hour for 4 h for in vitro measurements. Samples were
used within 2 h of collection to avoid any activation of platelets, monocytes or plasma
fibrinogen.
2.7. Platelet aggregometry
Rabbit platelet aggregation was assayed based on the Born’s turbidimetric method using a
Chrono-Log optical aggregometer as previously described [1]. Briefly, citrated blood (1:10
blood to ACD) was collected (6 ml) and platelet-rich plasma (PRP) was obtained by
centrifugation at 110× g for 15 min. Platelet-poor plasma (PPP) was obtained by another
centrifugation of the PRP-removed blood sample at 2730× g for 15 min and was used as the
blank for aggregation. PRP was incubated for 10 min at 37 °C and then 40 μg/ml collagen
(Chrono-PAR #385 Havertown, PA) was added. The percentage of aggregation was
determined 3 min after the addition of collagen using Chrono-Log Aggrolink software.
2.8. Flow cytometry
To determine platelet P-selectin (CD62P) and IIb/IIIa (fibrinogen receptor) expression, 100
μl of diluted blood aliquots (1:100 dilution of blood to Hank’s Balanced Salt Solution
(HBSS) without CaCl2 and MgCl2) were directly prepared for cell surface staining of P-
selectin and IIb/IIIa. In four 12 × 75 polypropylene tubes containing 100 μl of diluted blood,
40 μg/ml collagen (4 μl 1000 μg/ml) was added to two tubes and 4 μl saline was added to
the other two tubes. At this point, saturating concentrations (10 μl) of monoclonal anti-
human IIIa FITC and monoclonal anti-human CD62P PE antibodies were added to one of
the collagen and one of the saline treated tubes and incubated for 15 min at room
temperature (RT) in the dark. In the other two tubes containing collagen and saline, 10 μl
each of anti-mouse IgG1 FITC and PE were added as nonbinding isotype controls and also
incubated for 15 min at RT in the dark. After the antibody incubation step, each tube
received 700 μl of freshly prepared 1% formaldehyde buffer (in dPBS) and was stored at 4
°C until ready for flow cytometric analysis. To determine monocyte CD11b and CD14
expression, 100 μl of the undiluted blood aliquots were directly prepared for cell surface
staining of CD11b and CD14. At this point, saturating concentrations (10 μl) of rat anti-
mouse CD11b Alexa Fluor 488 and monoclonal anti-human CD14 PE antibodies were
added to one tube and 10 μl each of anti-rat IgG2b Alexa Fluor 488 and anti-mouse IgG2a PE
were added as nonbinding isotype controls. All tubes were incubated for 30 min at 4 °C in
the dark. After the antibody incubation, lysing of red blood cells was accomplished by
adding 2 μl of FACSLysing Buffer (Becton Dickinson San Jose, CA), gentle vortexing and
then incubating for 10 min at room temperature in the dark. After red blood cell lysing,
centrifugation at 250× g for 5 min at 4 °C pelleted the stained leukocytes. After aspirating
supernatant, one wash step was done with wash buffer containing dPBS, 0.1% sodium azide
and 0.5% bovine serum albumin, and then the the sample was centrifuged again and the
resulting supernatant was aspirated. The cells were then resuspended in 250 μl of freshly
prepared 1% formaldehyde buffer and stored at 4 °C until ready for flow cytometric
analysis. A FACSCalibur flow cytometer (Becton Dickinson San Jose, CA) was used for the
acquisition of flow data and the CellQuest software was employed for data analysis. Cell
populations were identified for data collection by their forward scatter (FSC) and side scatter
(SSC) light profiles. For each sample, 30,000 total events were collected. Fluorescence
intensity of immunostaining was quantitated by a histogram log plot analysis. Mean
fluorescent intensity (MFI) was expressed as the geometric mean channel fluorescence
minus the appropriate isotype control.
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2.9. In vitro plasma copper assay
The in vitro plasma copper assay (DICU-250, Gentaur, Accurate Chemical & Scientific
Corporation York, NY) was performed in a 96-well format to determine the amount of
copper leaching into the blood of the rabbits from the ECC over the 4 h experimental period.
Briefly, both baseline and 4 h plasma samples were treated with 30% trichloroacetic acid.
Samples were centrifuged at 14,000 RPM for 5 min and 100 μl of the supernatant was
collected. Each sample was diluted 1:2 with deionized water and 100 μl placed in a 96-well
plate. A copper standard (1.5 mg/dl CuSO4) was serial diluted and 100 μl of each
concentration, ranging from 0 to 300 μg/dl, was placed in separate wells. A working reagent
mix containing 0.9% ascorbic acid, 0.1% 4,4′-dicarboxy-2,2′-biquinoline, 2% NaOH and 8%
Hepes-free acid was then added to each well of the 96-well plate and mixed. After a 5 min
incubation, absorbance measurement of the plate was performed at 359 nm on a Synergy 2
microplate reader (Biotek Winooski, VT). All measurements were done in duplicate. Using
a linear regression curve from a copper standard (0–300 μg/dl), sample copper
concentrations were calculated. In addition, to determine the long-term copper leaching
levels from the NOGen polymer-coated ECC, an in vitro study which involed serially
sampling saline bathing solution that was equilibrated withiin the ECC for up to7 d was
carried out.
2.10. Plasma fibrinogen Aγ dimer expression via Western immunoblot
Plasma from the citrated whole rabbit blood collected over the 4 h experimental period for
each NOGen or control polymer coating plus infusion of either SNAP or saline was used for
a Western blot analysis of plasma fibrinogen Aγ dimer expression. After the −70 °C-stored
samples were rapidly thawed in a 37 °C water bath, an aliquot of 0.2 μl of plasma mixed
with Laemmli sample buffer containing 2% β-mercaptoethanol and incubated for 5 min at
95 °C were run on a 7.5% sodium dodecyl sulfate-polyacrylamide gel using a Bio-Rad
miniblot electrophoresis system (Criterion Hercules, CA). Protein was transferred onto
poly(vinyl-difluoride) membranes for 2 h at 1 amp. Membranes were blocked with Tris-
buffered saline containing 0.05% Tween 20 and 3% nonfat dry milk (Bio-Rad) for 1 h at
room temperature followed by an overnight incubation at 4 °C with FITC conjugated goat
anti-human fibrinogen antibody with gentle rocking. The membranes were washed twice for
10 min each and then imaged in a fluorescence imager (Bio-Rad VersaDoc MP4000
Hercules, CA). The Aγ and γ fibrinogen subunit densities were quantified using Quantity
One software (Bio-Rad). The Aγ dimer density was calculated as a ratio of the Aγ dimer
band over the sum of dimers plus monomers.
2.11. Statistical analysis
Data are expressed as mean ± SEM (standard error of the mean). Comparison between the
various wt.% of NOGen and control polymer groups were analyzed by the one-way
ANOVA with a multiple comparison of means using Student’s t-test. All statistical analyses
were performed using the statistical program SAS JMP (SAS Institute Cary, NC). The
immunoblot analysis of the Aγ dimer expression was statistically compared by the Student’s
t-test. Values of P < 0.05 were considered statistically significant for all tests.
3. Results
3.1. Cuo-nanoparticle/SP-60D-60 polyurethane (NOGen) polymer characteristics
It is well known that copper ions can catalyze the reduction of S-nitrosothiols to NO. Hence,
initially a NOGen polymer that contained a lipophilic Cu(II) complex (analogue to cyclen)
shown in Fig.1A (Cu(II)-dibenzo[e,k]-2,3,8,9-tetraphenyl-1,4,7,10-tetra-
azacyclododeca-1,3,7,9-tetraene (Cu(II)-DTTCT)) incorporated at 5 wt.% into plasticized
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PVC was evaluated as the inner wall coating in the rabbit extracorporeal circulation (ECC)
model. After 4 h of blood exposure the Cu(II) ligand complex showed marked reduction in
NO release (0.5–1 vs >20 × 10−10 mol cm−2 min−1 baseline) and platelet count (data not
shown). This was traced to significant heterogeneity of the lipophilic complex on the
surface, and subsequent sloughing off and/or passivation of the copper(II) complex active
material. An improved NOGen polymer was constructed that incorporated copper
nanoparticles in a hydrophilic polyurethane (Fig. 1B) that would allow Cu(II) ions to be
generated locally via very slow corrosion of the nanparticles to form trace levels of catalytic
copper ions to generate NO from the circulating RSNOs. Therefore, these copper particle-
containing NOGen polymer coatings were used for the rest of the ECC studies reported
herein. The mechanism of NO generation is dependent upon the polymer being hydrophilic,
and thereby allowing both the blood-borne low molecular weight S-nitrosothiols, such as S-
nitrosocysteine and S-nitrosoglutathione, to come in contact with the reduced ionized Cu (I)
species and generate NO from the RSNOs (Fig. 2A) (in the hydrophilic PU layer) before
these ions are completely scavenged by proteins in the plasma phase of the blood. The NO
generated from the circulating S-nitrosothiols by the copper-containing polymer make it a
reasonable material because of the potential unlimited supply of generated NO at levels that
exceeds the physiological NO release from endothelial cells (0.5–4 × 10−10 mol cm−2
min−1) [21]. As shown in Fig. 2B, NO generation from ECC circuits with the NOGen
polymer, as measured via a chemiluminescence NO analyzer, was obtained by adding 1 μM
GSNO to the piece of NOGen polymer-coated tubing. The 1, 5 and 10 wt.% copper particle
polymers provided NO fluxes that peaked at 5 ± 1, 10 ± 2 and 12.4 ± 2 × 10−10 mol cm−2
min−1, respectively. The ability of the coating to release steady-state levels of NO in
physiological buffer was achieved for the 4 h period by the continuous IV infusion of an
RSNO, SNAP, during the ECC procedure. Most importantly, it was confirmed that the NO
released from the NOGen ECC was not significantly reduced after 4 h of blood exposure, as
shown in Fig. 2B. Indeed, a piece of tubing removed from the circuit post-experiment and
measured for NO generation in the presence of GSNO, yielded nearly the same or slightly
less NO compared to the pre-blood exposure levels. This suggests that the blood
environment (i.e., proteins, cells, etc.) did not alter the kinetics of the NO release from the
Cuo-nanoparticle-containing NOGen coating.
To determine if plasma protein adsorption and in particular, human fibrinogen, occurs with
this polymer, an in vitro immunofluorescence assay was performed. The NOGen polymer
coatings (1, 5 and 10 wt.% Cu(II) particle NOGen polymer) exhibited significant human
fibrinogen adsorption compared to the non-nanoparticle control polymer (Fig. 3). The
adsorption of the human fibrinogen to the 5 and 10 wt.% Cu(II) particle polymers were
similar.
Since Cu(I/II) ions are released from the Cu nanoparticles in an aqueous environment, Cu
corrosion occurs at the polymer coating surface which leads to leaching of Cu(II) and Cu(I)
ions into the systemic circulation. The question at this point is what amount of Cu(II) ions
are actually present in the systemic circulation after the 4 h blood exposure and to determine
this level of copper ions in the plasma via a colorimetric plasma copper assay. After 4 h of
blood flow, the 1, 5 and 10 wt.% Cu particle polymer ECCs demonstrated a 1, 1.2 and 1.3
fold increase, respectively, in total plasma copper concentrations compared to the baseline
(i.e., no ECC present) plasma copper levels with either SNAP or saline systemic infusion
(Fig. 4A). The non-Cuo-nanoparticle control ECC plus SNAP actually showed a reduction in
plasma concentration of Cu(II) compared to the baseline levels (122 ± 13 vs 178 ± 5 μg/dl,
respectively). In addition, if the rate of Cu(I/II) leaching into the plasma from the Cuo-
nanoparticle doped polymer coating is 1.3 fold increase after 4 h what would be the leaching
be after 24 h or even 7 days? As shown in Fig. 4B the copper concentration was measured in
saline which resided in 10 wt.% Cu particle polymer-coated and non-Cu particle control
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ECCs for up to 7 d at room temperature. As expected, the non-Cuo-nanoparticle control
ECCs had no Cu(II) present over the 7 d. The 10 wt.% Cu particle ECC did accumulate up
to 23.4 ± 8 μg/dl Cu(II) in the saline solution after 7 d. The 4 h accumulation was 5.9 ± 6.2
μg/dl which indicates a very slow rate of copper corrosion to copper ions within the coatings
containing the copper nanoparticles.
3.2. Effects of NOGen polymer plus SNAP infusion on rabbit hemodynamics and thrombus
formation
Hemodynamic effects of 10 wt.% Cuo-nanoparticle NOGen- and non-Cuo-nanoparticle
control-coated ECC plus SNAP infusion over 4 h of blood exposure in the rabbit model of
thrombogenicity are shown in Table 1. Maximal hemodynamic effects were observed with
the 10 wt.% Cu particle polymer due to the maximal NO generation potential of this
material. Mean arterial blood pressure (MAP) within 2 h on ECC significantly fell when
using the 10 wt.% NOGen/SNAP group but returned to baseline levels after 4 h. This
returned in MAP to baseline is due to the continuous IV fluid maintenance at 33 ml/kg/h.
Heart rate for the NOGen and control ECC groups were unchanged over the 4 h. The blood
flow through the ECC was dependent upon MAP and after 4 h increased due to the added IV
fluids. Not unexpected, the activated clotting time (ACT) after 4 h on the NOGen or control
polymer ECCs increases, probably due to the increase in intravascular fluids, i.e.,
hemodilution effect. The total white blood cell (WBC) count remained unchanged over the 4
h for either ECC group of animals. The total WBC count is composed of lymphocytes,
monocytes and granulocytes.
To ascertain the differential formation of thrombus in the thrombogenicity chamber (i.e., the
3/8 inch ID Tygon tubing 8 cm in length) of the 1, 5, 10 wt.% NOGen or non-Cuo-
nanoparticle control polymer-coated ECC, 2-dimensional (2D) image analysis was
performed after 4 h of blood exposure. The thrombus area was analyzed by using the Image
J imaging software and represents the 2D area of thrombus formation (pixels/cm2) in each
tubing chamber. These thrombi area measurements were quantitated and, as shown in Fig. 5,
the thrombus area of the 5 and 10 wt.% Cuo-nanoparticle NOGen polymer ECC/SNAP
infusion were significantly smaller when compared to the non-Cuo-nanoparticle control
polymer ECC plus SNAP. Interestingly, the half-dose of SNAP plus the 10 wt.% Cuo-
nanoparticle NOGen polymer ECC also had a significant reduction in the thrombus
formation. However, 10 wt.% Cuo-nanoparticle polymer/saline formed as much thrombus as
the non-Cuo-nanoparticle control plus a full dose of SNAP. Thus, only when the copper
nanoparticle doped coating is used in combination with exogenous addition of RSNOs to the
blood, can a significant reduction in thrombus formation be observed. This suggests that the
levels of endogenous RSNOs are not adequate to produce the surface of levels of NO
required to substantially decrease platelet activation and subsequent thrombus formation.
3.3. Effects of NOGen polymer and SNAP infusion on rabbit platelet function and surface
receptor expressions
Platelet function during exposure to NOGen and control polymer-coated ECC was assessed
by observing platelet count (Fig. 6A) and the level of plasma fibrinogen, to which activated
platelets bind (Fig. 6B). Both platelet count and plasma fibrinogen levels were corrected for
hemodilution due to the added IV fluids. The 10 wt.% Cuo-nanoparticle NOGen polymer-
coated ECC plus SNAP infusion showed the greatest preservation of platelet count and
plasma fibrinogen levels over the course of the 4 h blood exposure while the non-copper
particle control polymer ECC plus SNAP showed a time-dependent loss in platelet count
and plasma fibrinogen levels. The 10 wt.% Cuo-nanoparticle NOGen ECC/SNAP was able
to maintain platelet counts to 90% or greater even at 3 and 4 h of blood exposure when
compared to the non Cuo-nanoparticle control polymer ECC/SNAP (Fig. 6A). Both the 1
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and 5 wt.% Cuo-nanoparticle NOGen ECCs plus SNAP infusion did not preserve platelets to
the same degree as the 10 wt.% Cu particle/SNAP group. In Fig. 6B, plasma fibrinogen
levels are shown to be unchanged in both the 10 wt.% Cuo-nanoparticle NOGen with full or
half-dose of SNAP compared to the non-Cuo-nanoparticle control ECCs plus SNAP.
Interestingly, there was no difference between the 1 and 5 wt.% Cuo-nanoparticle NOGen
coatings plus SNAP and the non-Cuo-nanoparticle control polymers and SNAP in their
ability to preserve plasma fibrinogen at any time point.
The percent of platelet functional aggregation, as determined by ex vivo collagen (40 μg/ml)
stimulation of PRP, was measured by optical turbidity (Fig. 7). The ability of platelets to
aggregate was only maintained with the 10 wt.% Cuo-nanoparticle NOGen polymer ECC
plus half-dose of SNAP whereas platelets from the 10 wt.% Cuo-nanoparticle ECC plus full
dose of SNAP were significantly reduced in their ability to aggregate upon collagen
stimulation, especially at the 3 and 4 h time points (Fig. 7).
To ascertain if the observed reduction in platelet aggregation with the 10 wt.% Cuo-
nanoparticle NOGen polymer after 4 h blood exposure was due to direct effects on platelet
activation, expression of the platelet membrane adhesion glycoprotein, P-selectin (CD62P),
was measured by fluorescence-activated cell sorting (FACS) analysis. When platelets
become activated, the surface expression of P-selectin increases [22]. As shown in Fig. 8A,
the unstimulated P-selectin expression was unchanged after 4 h for all experimental groups
except the 10 wt.% Cuo-nanoparticle plus saline group which showed an increase in
unstimulated P-selectin expression as compared to the unstimulated (i.e., no exogenous
collagen) baseline (no ECC present). However, 40 μg/ml collagen significantly stimulated
an increase in P-selectin expression at baseline and after 4 h for all NOGen ECC groups.
The collagen-stimulated P-selectin expression for the 4 h time point for the 10 wt.% Cuo-
nanoparticle ECC plus saline had an increase in P-selectin of 10 ± 3 mean fluorescence
intensity (MFI) while the 1,5,10 wt.% Cuo-nanoparticle NOGen ECC with a full dose of
SNAP and 10 wt.% Cuo-nanoparticle NOGen ECC plus a half-dose of SNAP were
significantly increased 16 ± 1, 18 ± 2, 13 ± 2 and 19 ± 1 MFI, respectively, from the
collagen-stimulated baseline (no ECC) levels.
In order to understand if the Cuo-nanoparticle-containing NOGen polymer can induce
changes in the IIb/IIIa (fibrinogen) receptor, a specific antibody to IIIa (CD61) was used to
evaluate platelet surface expression of IIb/IIIa via flow cytometry. As shown in Fig. 8B, the
platelet IIIa surface expression after 4 h for all NOGen ECC groups was unchanged
compared to the no ECC baseline levels. The IIIa expression, however, significantly
increased with 40 μg/ml exogenous collagen at baseline and after 4 h for all NOGen ECC
groups.
3.4. Effects of NOGen polymer on rabbit surface receptor expressions of monocytic
integrin, CD11b, and the constitutive monocyte-specific receptor, CD14
To determine if the NOGen polymer in the ECC can increase the surface integrin, CD11b,
expression on circulating monocytes that translates into activated monocytes, FACS analysis
of rabbit whole blood at baseline (no ECC) and after 4 h of circuit blood exposure was
performed. An increase in CD11b expression on circulating monocytes indicates a response
to an early inflammatory event [23]. The CD11b expression on rabbit monocytes was
observed to significantly increase 3-fold after 4 h blood exposure to the control polymer
ECCs, but all Cuo-nanoparticle-containing NOGen polymer ECCs exhibited no change in
the CD11b expression from the no ECC baseline situation (Fig. 9). The CD11b expression
observed with the NOGen polymer 4 h after blood exposure was also significantly reduced
from that observed after 4 h on control polymer ECC. If the circulating monocytes are
becoming activated, as indicated by the increase in CD11b expression, then the number of
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circulating monocytes as marked by the constitutive surface receptor, CD14, should be
decreased. After 4 h of blood exposure the non-Cuo-nanoparticle control ECC plus SNAP
did show a significant decrease in CD14 expression indicating a loss of circulating
monocytes compared to the no ECC baseline levels. The Cuo-nanoparticle-containing
NOGen ECCs with SNAP or saline showed no change from baseline in the number of
circulating monocytes after 4 h of blood exposure.
3.5. Effects of NOGen polymer on Aγ dimer formation in plasma fibrinogen
In order to determine why 10 wt.% Cuo-nanoparticle ECC plus SNAP infusion would
attenuate platelet aggregation but maintain normal expression of platelet P-selectin,
activation of plasma fibrinogen was investigated for an increase in the amount of Aγ
heterodimer by Western immunoblot assay. In the biosynthesis of fibrinogen, the formation
of Aγ heterodimers linked by disulfide bonds is suggested to be an intermediate in the
assembly of fibrinogen [24]. Conformational changes in fibrinogen structure via equilibria
between thiols and disulfide bonds have been observed and found to inhibit thrombin-
catalyzed fibrinogen polymerization [25]. In Fig. 10, when plasma samples from animals
exposed to 10 wt.% Cuo-nanoparticle ECC plus SNAP, non-Cuo-nanoparticle ECC plus
SNAP, and the 10 wt.% Cuo-nanoparticle plus saline infusion were run on a reduced SDS-
PAGE gel, the percent level of the Aγ dimer to total Aγ dimer + γ monomer was
significantly reduced in the case of the 10 wt.% Cuo-nanoparticle NOGen/SNAP group
when compared to either the non-Cuo-nanoparticle ECC/SNAP or 10 wt.% Cuo-nanoparticle
ECC/saline groups.
4. Discussion
In vivo testing of the Cuo-nanoparticle-containing polymer coating in an extracorporeal
circuit with exogenous RSNOs demonstrated that the NOGen polymer can generate NO,
preserve platelet count and maintain monocyte inactivation after at least 4 h of blood
exposure in a rabbit model of thrombogenicity. However, even though overall platelet
number was preserved, functional platelet aggregation was inhibited with the 10 wt.% Cuo-
nanoparticle-coated ECC plus exogenous SNAP addition after the 4 h of blood exposure.
Direct platelet activation, in contrast, was not inhibited by the NOGen polymer and SNAP
infusion as measured by the platelet surface glycoprotein, P-selectin, expression but the
platelets did respond to exogenous collagen in a fashion similar to a no ECC sample. In
order for platelets to have a normal response to an agonist stimulation such as collagen but
have an inhibited aggregation response would indicate that some plasma factor promoting
platelet aggregation might be adversely affected by both the NO generated by the NOGen
polymer and the excess RSNOs present in the platelet-rich plasma (PRP). Since plasma
fibrinogen is the protein the actively binds to activated platelets and provides the means for
platelet aggregation, alterations in plasma fibrinogen, and not the platelets per se, might be a
basis for the preservation of platelets and enhanced hemocompatibility of the 10 wt.% Cuo-
nanoparticle NOGen polymer plus SNAP in the extracorporeal circuit.
Previous work, including ours, has established that NO releasing polymers (NORel) can
prevent loss of circulating platelets and monocytes [1,5,26–32]. This provides significant
evidence for the importance of NO in defining, in part, the hemocompatibility of
biomaterials used in ECLS. However, even though the NORel polymer provides this
preservation on platelets and maintain their ability to aggregate, this polymer has only a
finite amount of NO that can be loaded and released over time during extracorporeal
circulation (ECC). As presented here, the Cuo-nanoparticle NO generating (NOGen)
polymer plus a consistent supply of exogenous RSNOs (i.e., SNAP in this case), should
provide a more continuous generation of NO at the blood/polymer interface. Indeed, via use
of such a system, we have shown that platelet and monocyte counts are maintained not by
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direct platelet P-selectin attenuation but possibly through a structural alteration of the
plasma fibrinogen that prevents the functional aggregation of activated platelets. The only
difference thought to exist between the Cuo-nanoparticle NOGen polymer/SNAP system and
the previously studied diazeniumdiolate-based NORel polymers is how NO is locally
delivered to the blood and circulating platelets as well as monocytes flowing through the
ECC. As previously reported, the degree of thrombosis and ECC-induced expression of
platelet P-selectin and monocyte CD11b were attenuated with the NORel polymer [1] but,
with the Cuo-nanoparticle NOGen polymer/SNAP-configured system used in this work, the
platelet P-selectin expression was not attenuated while the degree of ECC-induced
thrombosis and monocyte CD11b expression were decreased similar to that observed with
the NORel polymer systems. The underlying threshold level of locally-released NO from the
Cuo-nanoparticle NOGen polymers was concentration-dependent upon the wt.% of the Cu
particle in the SP-60D-60 PU with a maximum NO released level of 12 × 10−10 mol cm−2
min−1 prior to and 10 × 10−10 mol cm−2 min−1after 4 h of blood exposure achieved in the
10 wt.% Cuo-nanoparticle polymer. Using this level of Cuo-nanoparticle-containing
polymer, our results further confirm our previous NORel data showing that this amount of
NO flux nearly matches that seen with NORel, i.e., approx. 15 × 10−10 mol cm−2 min−1.
Interestingly, the lower concentrations of Cuo-nanoparticles in the NOGen polymer (i.e., 1
and 5 wt.%) plus the SNAP infusion were not as effective in the in vitro NOA-measured NO
release (5 × 10−10 and 8 × 10−10 mol cm−2 min−1, respectively) or in the preservation of
platelets as compared to the 10 wt.% Cuo-nanoparticle NOGen polymer/SNAP effects.
Although the in vitro NO generation level from the 10 wt.% Cuo-nanoparticle NOGen
polymer was similar to the level released by the previous NORel materials, there was a
significant contrast in the in vivo levels of plasma fibrinogen and platelet function as
measured by aggregometry and P-selectin upregulation. Interestingly, the in vivo
combination of both the Cu catalyst in the ECC polymer and the added SNAP, was needed
to maintain an environment of continuous NO release and the desired hemostatic effects.
The level of plasma fibrinogen was reduced in all rabbit groups but the 10 wt.% Cuo-
nanoparticle polymer plus either the full or half-dose of SNAP and the 5 wt.% Cu polymer
plus SNAP groups. The in vitro human fibrinogen immunoassay showed that fibrinogen
adsorbed significantly to all the 1, 5 and 10 wt.% Cuo-nanoparticle NOGen polymer surfaces
and confirmed that the loss of rabbit plasma fibrinogen was more likely due to adsorption to
the ECC surface in the non-Cuo-nanoparticle/SNAP, 10 wt.% Cuo-nanoparticle/saline or 1
wt.% Cuo-nanoparticle/SNAP groups but not in the 5 and 10 wt.% Cuo-nanoparticle ECC in
the presence of the added SNAP. The increase in the in vitro fibrinogen adsorption is
perhaps due to the roughness of the surface that develops with the Cu particles near the
blood/polymer interface. However, the in vivo fibrinogen adsorption especially with the 10
wt.% Cuo-nanoparticle ECC was in the presence of SNAP and the generated NO may
prevent the fibrinogen from adsorbing in an as yet unclear mechanism (perhaps nitrosation
of the protein). This issue warrants further investigation. In addition, in the 5 and 10 wt.%
Cuo-nanoparticle ECC plus the infused SNAP groups, platelet P-selectin upregulation was
not attenuated as in the NORel polymer but remained unchanged from baseline, while the
ability of the platelet to aggregate upon collagen stimulation was markedly reduced. This
suggests that the added SNAP and high amount of Cu catalyst does not affect the platelet per
se, but does influence an entity that is needed to promote platelet aggregation. The entity
that may be affected by the Cu/SNAP combination could be the structure of plasma
fibrinogen so that it is rendered unavailable for aggregating platelets.
Another aspect of the Cu catalyst/RSNO combination is the level of Cu(II) that leaches into
the ECC blood due to copper particle corrosion and the excess RSNO, SNAP, that is infused
intravenously. First, the corrosion rate for the 10 wt.% Cuo-nanoparticle polymer in saline
was found to be 11.4 + 4.1 μg/24 h. However, even after 7 d the rate was only 23.4 + 8.0 μg/
7 d. To put this into perspective, the U.S. Institute of Medicine recommends the daily Cu
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intake be 900 μg/day while the tolerable upper limit of intake to be 10,000 μg/day in adults
[33]. Therefore, it is unlikely that in only 4 h of blood contact, even with a 10 wt.% copper
particle-coated ECC circuit, that the level of Cu(II) leaching would reach anything close to
toxic levels. The Cu(II) levels are actually less than 1% of the tolerated upper Cu intake
level. Even though the Cu(II) levels are at well-tolerated levels, it is actually Cu(I) that is
needed to generate NO from the RSNO. However, in cells and in blood, due to its highly
reactive nature, Cu(I) is rapidly converted to Cu(II) via reaction with oxygen and other
species. In addition, the vast majority of all copper ions within blood is complexed = to
albumin and ceruloplasmin which carries 95% of the plasma copper ions and only 0.2 pM is
in free Cu(II) or Cu(I) [34]. Any excess Cu(II) from the Cu ion leaching from the Cuo-
nanoparticle-containing ECC is ultimately taken up by ceruloplasmin or albumin but not
before RSNO (SNAP) decomposition occurs within the hydrophilic PU coating. Secondly,
the infused SNAP itself, which provides the ability of the Cuo-containing ECC to release a
continuous level of NO, may also have other biological effects. One of the prominent effects
elicited by the systemic infusion of SNAP was marked hypotension. The co-administration
of intravenous fluids counteracted the blood pressure fall but this could pose significant
difficulties in a clinical situation. SNAP administration has been shown to cause
hypotension [35], hyperglycemia [36] and decreased cell viability [37–39]. However, most
of these adverse effects are ameliorated in the presence of endogenous thiols and superoxide
dismutase. Future NOGen polymers should, therefore, reduce the need for systemic
administration of RSNOs used in ECLS by co-incorporating a pool of RSNOs within the
polymer coating, allowing the NO regeneration and nitrosation of reduced thiols to occur
locally at the blood/polymer interface.
Not only does the aforementioned immobilized Cu particle-containing polymer and excess
SNAP, generate NO, decrease thrombus formation, maintain platelet P-selectin expression
upon collagen stimulation, and attenuate monocyte activation, but our results also show a
marked influence on platelet aggregation and plasma fibrinogen Aαγ dimer assembly which
all have a strong dependency on the level of Cu(II) and SNAP present. The generated NO
from the Cuo-nanoparticle ECC/SNAP combination appears to inhibit the functional ability
of platelets to aggregate, but the platelets themselves still maintain the capacity to respond to
prothrombotic agonists such as collagen as measured by the upregulation of P-selectin. As
our previous work with the NORel polymer had shown, the P-selectin expression upon
collagen stimulation is attenuated and followed the aggregometry response [1]. The question
that arises is why is there a different response of the platelets for the NORel circuits and the
currently studied Cuo-nanoparticle NOGen ECC and added SNAP combination?. The
important difference between the two NO producing ECC systems is the added SNAP. S-
nitrosothiols, biologic molecules that serve an important role in the transport, storage and
metabolism of NO, are sulfhydryl-containing plasma and cellular proteins that have reacted
with and bound nitrosonium ions [40]. S-nitrosylation of cysteine residues within a broad
functional spectrum of proteins constitute a large part of the ubiquitous influence of NO on
physiological responses. The posttranslational modifications and functional regulation of
both plasma and intracellular proteins is mediated through the S-nitrosylation mechanism
[41]. Several proteins have been identified as S-nitrosylated proteins including soluble
guanylate cyclase mediates production of intracellulear cyclic GMP (i.e., part of the NO-
mediated cell signaling pathway) [42], platelet IIb/IIIa receptor binding to fibrinogen [43–
45] and fibrinogen itself [25,46]. Geer et al. recently showed that glutathione and its
derivatives including the nitrosated form, S-nitrosoglutathione, interact with several
fibrinogen subunits especially the Aα subunit, alter its structure and inhibit fibrin
polymerization upon activation [46]. Our results support their results by showing a reduction
in the heterodimer Aαγ formation which is part of the early fibrin polymerization process. It
is hypothesized that NO is transnitrosated from the infused SNAP to cysteines in the Aα and
γ subunits of fibrinogen which explains our attenuated platelet aggregation but no effect on
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the ability of the platelet to respond to collagen stimulation. Further studies are planned to
verify this proposed mechanism.
5. Conclusions
This study has demonstrated that coating a solution of SP-60D-60 polyurethane containing
copper (Cu) nanoparticles (25–50 nm) on PVC tubing can continuously generate and release
NO for at least 4 h in a rabbit model of extracorporeal circulation. Significant amounts of
NO generation appear to occur when an exogenous source of S-nitrosothiol is infused
continuously (S-nitroso-N-acetylpenicillamine (SNAP)). The generation of NO, for example,
from a10 wt.% Cuo-nanoparticle doped polymer coating plus an exogenous infusion of the
SNAP has been shown to preserve circulating platelets, both in count and function, as
measured by P-selectin expression but not via aggregometry. The platelet count preservation
appears to be promoted by direct effects on the structure of assembled plasma fibrinogen by
the interaction of Cu(I) and SNAP to generate NO and not as much on the ability of platelets
to be activated. These results indicate the potential of locally generating NO via the
continuous interaction of Cu(I) ions with S-nitrosothiols to increase hemocompatibility of
extracorporeal circuits and devices. In addition, this locally generated NO at the blood/
polymer interface was found to be dependent upon the presence of both an exogenous
source of RSNO and the copper catalyst, with dramatically less effect from including the
RSNO source alone with the control coatings. Studies investigating improvements of the
NOGen polymer in order to reduce the amount of exogenous RSNO administration
systemically and Cu(II) leaching are planned for future studies. The NOGen polymer
coatings described here have the potential to provide a and attractive approach in creating
hemocompatible surfaces for a wide range of ECC-based therapies that cannot be fully
addressed with direct NO releasing polymeric coatings (e.g., NORel).
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Fig. 1.
NO generating (NOGen) fabrication. (A) Schematic of polymer containing a lipophilic
Cu(II) complex (analogue to cyclen) (Cu(II)-dibenzo[e,k]-2,3,8,9-tetraphenyl-1,4,7,10-
tetraaza-cyclododeca-1,3,7,9-tetraene (Cu(II)-DTTCT)) and incorporated at 5 wt.% into
plasticized PVC. This was coated as 1 active layer on PVC tubing. (B) Schematic of
SP-60D-60 polyurethane containing 25–50 nm copper nanoparticles that is layered as 2
active coats on PVC tubing.
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Fig. 2.
(A) A working hypothesis of the NO release from circulating RSNO which is catalyzed by
Cu(I) ions that are reduced from Cu(II) ions released through corrosion of the copper
particle in polymer. (B) NO releasing characteristics as measured by NOA
chemiluminescence. NO surface flux prior to and after 4 h of blood exposure. The data are
means ± SEM. Significance was determined at a p < 0.05.
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Fig. 3.
In vitro fibrinogen adsorption assay on 1, 5 and 10 wt.% Cuo-nanoparticle-based NOGen
and control polymers. Fluorescence assay in a 96-well format that used a goat anti-human
fibrinogen-FITC conjugated antibody to measure the level of adsorbed human fibrinogen (3
μg/ml) to plated NOGen and control polymers. The data are means ± SEM. * = p < 0.05,
control vs NOGens.
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Fig. 4.
Plasma copper concentration assay. (A) Quantitation of the total copper concentration in
plasma of the various wt.% Cuo-nanoparticle-containing NOGen and control polymers prior
to and 4 h after ECC blood exposure. (B) In vitro time course of copper ion leaching from
10 wt.% NOGen and control polymers after 7 d in saline. The data are means ± SEM. * = p
< 0.05, control vs NOGens.
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Fig. 5.
Thrombus formation of 1, 5 and 10 wt.% Cuo-nanoparticle doped NOGen and control
polymer ECCs with and without SNAP infusion after 4 h blood exposure in the rabbit
thrombogenicity model. Quantitation of the thrombus area as calculated using Image J
software from NIH. The data are means ± SEM. * = p < 0.05, control ECC plus SNAP vs
NOGen ECCs after 4 h.
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Fig. 6.
Time-dependent effects of NOGen polymer ECC on rabbit platelet count (i.e., consumption)
(A) and plasma fibrinogen levels (B) after 4 h of blood exposure in rabbit thrombogenicity
model. Data is the mean ± SEM. * = p < 0.05, baseline vs control + SNAP and NOGen
ECCs. # = p < 0.05, control ECC + SNAP vs NOGen ECCs.
Major et al. Page 23
Biomaterials. Author manuscript; available in PMC 2012 September 1.
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
Fig. 7.
Time course of platelet aggregometry as measured by optical turbidity. Platelet-rich plasma
was prepared and the aggregation initiated by 10 μg/ml collagen. The data are means ±
SEM. * = p < 0.05, baseline vs control and NOGen ECCs.
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Fig. 8.
Fluorescent-activated cell sorting (FACS) analysis for circulating platelet P-selectin
(CD62P) after 4 h blood exposure with NOGen or control polymer-coated ECCs ±
exogenous SNAP. (A) Platelet P-selectin mean fluorescence intensity (MFI) after 4 h on
ECC with or without 40 μg/ml collagen stimulation in NOGen and control polymers. (B)
Platelet IIIa (CD61), subunit of the platelet fibrinogen receptor, mean fluorescence intensity
(MFI) after 4 h on ECC with or without 40 μg/ml collagen stimulation in NOGen and
control polymers. The data are means ± SEM. * = p < 0.05, unstimulated vs collagen-
stimulated for baseline, control ECC and NOGen ECCs. # = p < 0.05, collagen-stimulated
for baseline vs collagen-stimulated for control ECC and collagen-stimulated for NOGen
ECCs. The specific MFI data is after the isotype control value was subtracted from each P-
selectin MFI value. All FACS analyses used the gated FSC/SSC plot for platelets and 100 μl
of diluted whole rabbit blood (1:100) was used for each determination.
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Fig. 9.
Fluorescent-activated cell sorting (FACS) analysis for circulating monocytes after 4 h blood
exposure with NOGen or control polymer-coated ECCs with or without exogenous SNAP
infusion. (A), Monocyte CD11b mean fluorescence intensity (MFI) after 4 h on ECC in
NOGen and control polymers. (B) Monocyte CD14 (monocyte specific marker) mean
fluorescence intensity (MFI) after 4 h on ECC in NOGen and control polymers. The data are
means ± SEM. * = p < 0.05, baseline vs control ECC or NOGen ECCs. The specific MFI
data is after the isotype control value was subtracted from each CD11b or CD14 MFI value.
All FACS analyses used the gated FSC/SSC plot for monocytes and 100 μl of whole rabbit
blood was used for each determination.
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Fig. 10.
Western immunoblot analysis of rabbit plasma fibrinogen after 4 h blood exposure with 10
wt.% Cuo-nanoparticle NOGen ± exogenous SNAP or control polymer-coated ECCs plus
exogenous SNAP. (A), Representative immunoblot. Aliquots (0.2 μl) of reduced plasma
samples after 4 h on ECCs in NOGen or control polymers were separated on 7.5%
polyacrylamide gels, protein transferred to poly(vinyl-difluoride) (PVDF) membranes and
then immunostained with FITC conjugated goat anti-human fibrinogen antibody. Human
plasma fibrinogen was used to confirmed cross-reactivity of the anti-human antibody to
rabbit plasma fibrinogen. FGN = fibrinogen. Molecular weight markers are shown on left
with positions of the relevant fibrinogen chains and factor XIII indicated on the right. (B)
Western blot of plasma samples in (A), after 4 h on ECC in NOGen and control polymers,
were quantified by densitometry using Quanity One imaging software (Bio-Rad Hercules,
CA). The specific Aαγ dimer formation was calculated as the ratio (density) of the Aαγ
dimer band over the sum of dimers plus monomers. The data are means ± SEM. * = p <
0.05, baseline vs control ECC/SNAP or 10 wt.% Cu particle NOGen ECCs/± SNAP.
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